It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Ryals McMullian noted consumers are moving away from traditional white and wheat bread into organic, keto, gluten-free and ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

were listed among the drugs subject to Medicare pricing negotiations (as part of the Inflation Reduction Act) set to take effect in 2027. Which current and future GLP-1 manufacturers may be best ...

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

As Hain Celestial gears up to become a “pure play” food and beverage supplier, the company sees opportunities linked to GLP-1 ...

Opens in a new tab or window Just over half of patients with overweight or obesity discontinued their GLP-1 receptor agonist ... BCEPS International Symposium, Future of Science, Cell and Gene ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.